Table 5.
Prevalences and median titers of the anti-EBNA-1 and VCA IgG antibodies before and after 2-years of treatment with the different DMTs.
| Anti-EBNA-1 IgG | ||||||
|---|---|---|---|---|---|---|
| Prevalences | Median Titers (AU)* | |||||
| DMTs | Before | 2-years | p | Before | 2-years | p |
| TOTAL | 97.8% (318/325) | 98.5% (320/325) | n.s. | 25.4 | 25.7 | n.s. |
| IFN-beta | 96.9% (127/131) | 97.7% (128/131) | n.s. | 25.9 | 26.2 | n.s. |
| GA | 98.8% (82/83) | 98.8% (82/83) | n.s. | 25.4 | 26.0 | n.s. |
| NTZ | 98.2% (109/111) | 99.1% (110/111) | n.s. | 24.9 | 24.9 | n.s. |
| Anti-VCA IgG | ||||||
| Prevalences | Median Titers (AU)* | |||||
| DMTs | Before | 2-years | p** | Before | 2-years | p** |
| TOTAL | 99.7% (324/325) | 99.4% (323/325) | n.s. | 59.9 | 60.7 | n.s. |
| IFN-beta | 99.2% (130/131) | 99.2% (130/131) | n.s. | 58.6 | 59.8 | n.s. |
| GA | 100% (83/83) | 100% (83/83) | n.s. | 59.0 | 61.5 | n.s. |
| NTZ | 100% (111/111) | 99.1% (110/111) | n.s. | 61.1 | 61.6 | n.s. |
TOTAL: prevalence and median titers of all the different disease modifying therapies (DMTs); IFN-beta, interferon beta; GA, glatiramer acetate; NTZ, natalizumab. *Median values of the arbitrary units (AU). **Student t test (for titers) and Chi-square test (for categorical variables). n.s., not significant.